(Q35914405)

11 August 2017

1 reference

title

Role of aromatase inhibitors in the treatment of breast cancer (English)

1 reference

11 August 2017

Toni K Choueiri

1

1 reference

11 August 2017

Carlos A Alemany

series ordinal

2

1 reference

11 August 2017

Rony M Abou-Jawde

series ordinal

3

1 reference

11 August 2017

G Thomas Budd

series ordinal

4

1 reference

11 August 2017

language of work or name

1 reference

1 August 2004

1 reference

11 August 2017

Clinical Therapeutics

1 reference

11 August 2017

26

1 reference

11 August 2017

8

1 reference

11 August 2017

1199-1214

1 reference

Oestrogen exposure and breast cancer risk

11 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Concentration of sex steroids in adipose tissue after menopause

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Aminoglutethimide in treatment of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Resistance of the ovary to blockade of aromatization with aminoglutethimide

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Effect of estrogen deprivation on the reproductive physiology of male and female primates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Preoperative endocrine therapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Endocrine and clinical endpoints of exemestane as neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Aromatase inhibitors for chemoprevention

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Role of anastrozole in adjuvant therapy for postmenopausal patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Anastrozole: pharmacological and clinical profile in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Absolute bioavailability of letrozole in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

The pharmacology of letrozole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Prevention strategies with aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

Examining quality of life issues in relation to endocrine therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2980017-1

7 January 2021

10.1016/S0149-2918(04)80017-1

Identifiers

DOI

1 reference

11 August 2017

1 reference